10x Genomics Q3 2026: Revenue Beat, Big EPS Miss as Atera Launches

As seen on the 24/7 Wall St. homepage on November 5, 2026.

TXG 10x Genomics
Q3 2026
EPS
-$0.15
est -$0.02 -650.0%
Revenue
$151M
est $148M +1.9%

The Atera launch is behaving like a platform transition: instrument sales fell while spatial consumables climbed to $41.19 million, and management still raised full-year revenue guidance to $625 million to $635 million. Gross margin expanded to 75% from 67%, though litigation costs and other expense of $7.44 million pulled the bottom line below consensus.

Continue ReadingShow less

10x Genomics posted Q3 2026 revenue of $150.67 million, edging past the $147.85 million consensus by 1.91% and rising about 1% from a year earlier. The headline number held up better than it might have, given that instrument sales fell in both the single cell and spatial categories as customers held off purchases ahead of the new Atera platform.

Spatial consumables were the clearest bright spot, climbing to $41.19 million from $35.37 million a year ago. That consumables strength, along with lower inventory write-downs and a favorable product mix, helped push gross margin to 75% from 67%, a meaningful step forward for a company that has long been investing heavily in its product portfolio.

The earnings shortfall was harder to overlook. GAAP EPS came in at negative $0.15 against a consensus estimate of negative $0.02, a miss of 650%. Litigation expenses and other expense, net of $7.44 million, were a notable drag below the operating line, even as the operating loss itself narrowed to $16.06 million from $32.24 million a year earlier.

Sponsored

CEO Serge Saxonov pointed to commercial shipments of Atera as the quarter's biggest development, saying enthusiasm for the platform had continued to build and that the company was excited to be putting instruments in customers' hands. The company also introduced Sentira, a cloud analysis platform combining NVIDIA accelerated computing and Anthropic's Claude for spatial and single cell data analysis.

Management raised full-year 2026 revenue guidance to $625 million to $635 million, up from a prior range of $610 million to $630 million. Excluding non-recurring license and royalty revenue tied to patent litigation settlements in both years, that implies 4% to 6% growth over full-year 2025, with the Atera commercial ramp and consumables trajectory the two variables most worth tracking in coming quarters.

Mentioned: TXG